SAN DIEGO, Sept. 14, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate tedizolid phosphate (formerly known as torezolid phosphate and TR-701), will be presented in poster and slide presentations at the 51th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Chicago September 17-20. In addition to the results of clinical and nonclinical studies of tedizolid phosphate, the posters highlight advances in Trius’ preclinical GyrB antibacterial program that is targeting gram-negative pathogens, a class of bacteria rapidly developing resistance to existing antibiotics and for which there are few new antibiotics in development.
